Tuesday, February 10, 2026 | 05:03 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch
Sensex (    %)
                             
Nifty (    %)
                             
Nifty Midcap(    %)
                             
Nifty Smallcap(    %)
                             
Nifty Bank(    %)
                             
Nifty IT(    %)
                             
Home / Markets / Anthem Biosciences Ltd / News

Anthem Biosciences Ltd News

Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms

While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs

Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms
Updated On : 09 Jan 2026 | 11:20 AM IST

Nomura initiates Anthem with 'Buy', sees strong long-term CRDMO runway

The brokerage cited the company's strong positioning in India's fast-growing CRDMO space, high profitability and disciplined execution as reasons for its bullish view

Nomura initiates Anthem with 'Buy', sees strong long-term CRDMO runway
Updated On : 28 Nov 2025 | 8:33 AM IST

Recently listed biotech stock surges 44% against issue price; time to sell?

Shares of Anthem Biosciences surged 9 per cent to ₹820 on the BSE in Thursday's intra-day trade amid heavy volumes after reporting a strong earnings for the quarter ended June 2025.

Recently listed biotech stock surges 44% against issue price; time to sell?
Updated On : 14 Aug 2025 | 11:00 AM IST